Leerink Partners analyst David Risinger has maintained their bullish stance on TECX stock, giving a Buy rating yesterday.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
David Risinger has given his Buy rating due to a combination of factors that suggest a promising outlook for Tectonic Therapeutic. One key element is the differentiation in patient selection and enrichment strategies between TECX’s APEX trial and AZN’s Re-PHIRE trial. TECX focuses on a more specific patient group, which could potentially lead to more targeted and effective outcomes for their TX45 candidate.
Additionally, the upcoming results from AZN’s trial could have positive implications for TECX if they demonstrate broad efficacy, particularly in the PH-HFpEF CpcPH subgroup. This subgroup’s response is of particular interest due to its relevance to TECX’s targeted approach. Furthermore, the anticipation of detailed results from other competitors, such as LLY’s failed volenrelaxin candidate, could provide additional insights and opportunities for TECX to capitalize on its strategic positioning in the relaxin field.
TECX’s price has also changed dramatically for the past six months – from $42.600 to $23.160, which is a -45.63% drop .